• For Institutions

  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec4
Citigroup Analyst Maintains Buy Rating and Sets Target Price for Apellis Pharmaceuticals
01:07
Dec3
Apellis Pharmaceuticals Inc.'s EMPAVELI® Receives FDA Approval
22:05
Nov28
Geode Capital Management LLC Increases Stake in Apellis Pharmaceuticals
10:13
Nov18
Apellis Pharmaceuticals General Counsel Sold Company Stock
15:06
Nov14
H.C. Wainwright Analyst Maintains Buy Rating on Apellis Pharmaceuticals
23:42
Nov12
Apellis Pharmaceuticals Reports Five-Year Study Results of SYFOVRE® Treatment
12:01

Schedules & Filings

Schedules
Filings
Oct30
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 458.58 M, Net Income 215.72 M, EPS 1.67

Jul31
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 178.49 M, Net Income -42.15 M, EPS -0.3344

May7
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 166.8 M, Net Income -92.23 M, EPS -0.7351

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
NVDA
184.970
0.00%
0.000
AAPL
277.180
0.00%
0.000
GOOG
317.750
0.00%
0.000
GOOGL
317.080
0.00%
0.000
MSFT
492.020
0.00%
0.000
VTI
336.230
0.00%
0.000
AMZN
227.920
0.00%
0.000
AVGO
406.290
0.00%
0.000
VOO
628.100
0.00%
0.000
META
656.960
0.00%
0.000
View More